Our Products

Home Our Products

The Indenos

Development of the Indenos:

The Indenos were created specifically to address the shortcomings of conventional Top-1 Inhibitors. The NCI has invested significantly in all pre-clinical investigations and all 5 Phase 1 clinical trials for these compounds. Gibson Oncology, which owns the rights to the Indenos, now is planning Phase 2 trials for LMP400, LMP744, and LMP776.

Advantages of the Indenos

The Indenos have a large number of unique properties detailed below.

Irreversibly bound to tumor DNA at a unique site
Not subject to cancer cell efflux pumps which limit Irinotecan Topotecan use and produce toxicity
Work when Irinotecan fails
Much better safety profile with much less diarrhea and bone marrow suppression; critical in Pediatric patients where toxicity, especially diarrhea, often limits Irinotecan use.
Work synergistically with PARP Inhibitors in “Lethal” Combination.
Work in BRCA1-, BRCA2-, HER2- Breast Ovarian, and other cancers where homologous recombinant deficiencies
Work in patients with Genetic Variations of UGT1A1*28 metabolism which limits dosing of Irinotecan and consequent effects on life expectancy
Cross blood brain barrier.
Patient whose tumors have high Shlafen 11 are very sensitive to Indenos.
Potential Biomarkers for patient selection
Cost of Production low
Active and Growing US and International IP issued

Our Products

The Indenos

Development of the Indenos:

Advantages of the Indenos

The Indenos have a large number of unique properties detailed below.

Quick Links

For a complete Bibliography List, click below link :

Contact Us